Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
‘Avengers: Endgame’ Has Made 400 Million Yuan in China – And It’s Not Even Out Yet
Huawei Takes Second Crack at Brazilian Smartphone Market
China Confirms Date of Second Belt and Road Forum
LATEST
Politburo Warns of Lingering Pressure on Economy, Vows Support
Huawei Takes Second Crack at Brazilian Smartphone Market
‘Avengers: Endgame’ Has Made 400 Million Yuan in China – And It’s Not Even Out Yet
Sinovation-Backed Education Firm Secures $140 Million in New Funding
China ‘Regrets’ WTO Ruling on Agriculture Trade Restrictions
China Stock Photo Giant Fined for Trying to Copyright Black Hole
China Confirms Date of Second Belt and Road Forum
China Needs to Fight Nonfinancial Money Laundering, Global Body Finds
Buick Rolls Out First Electric Car for China
People’s Daily Website Reports Booming Profit
China’s Starbucks Rival Raises $150 Million in BlackRock-Led Round
National Rules on Online Lending Still Far From Sight
Cabinet Reaffirms No ‘Flood-Like’ Stimulus, Continued Support for Small Firms
Central Bank Injects Less Liquidity Than It Rolls Back
Transit Control System Provider Seeks $1.5 Billion IPO on New Tech Board
China Pushes to Restore Morale at Corruption-Tainted Science Institute
Anbang Cuts Registered Capital, Allowing Creditors to Demand Repayment
Vatican Accepts Invitation to Exhibit at China Horticulture Expo
Taiwan's Richest Man Announces Bid for Top Office, Citing Advice From Goddess
BAIC’s New-Energy Unit Expects Drop in Lower-End Sales as Subsidies Dry Up
Deadly 'Super Fungus' Fuels China Pharma Stock Surge

By Wang Luyao and Han Wei / Apr 12, 2019 03:40 AM / Finance

Photo: VCG

Photo: VCG

A number of Chinese pharma stocks surged Thursday after reports confirming domestic infections of a deadly fungus that is spreading around the globe, although none of the companies has a proven therapy.

Share prices of antifungal drugmakers listed in Shanghai and Shenzhen have climbed over the past few days. Several stocks rose by their 10% daily limits, including Jiangsu Lianhuan Pharmaceutical Co. and Jiangsu Sihuan Bioengineering Co.

At least 18 people in China are known to have been infected in recent years with Candida auris, although no deaths have been reported, Caixin learned. The fungus, which can cause deadly infections of the bloodstream and wounds in people with weakened immune systems, is often resistant to common antifungal drugs and is described as a “serious global health threat” by the U.S. Centers for Disease Control and Prevention.

Analysts said the pharma stock surges are mainly driven by hot money as none of the companies has been proven to have effective therapy against Candida auris.


Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.